The value at the next to last timestep in a trial, as a function of trial number (with initial values taken to be zero), is where r(t) is the reward at the end of trial t.
The relative difference between grass SLIT-tablet and placebo per trial (or season within a trial) as a function of the average grass pollen counts over the first 20 days, the last 20 days, the 15-day peak and the entire grass pollen season was modelled with a robust linear regression (lmRob; TIBCO Spotfire S+® 8.1 for Windows® TIBCO Software Inc., Palo Alto, CA, USA).
(A – D ) Estimates of the log prior-odds on a given trial as a function of belief on the previous trial (compare to Figure 1B ) computed for each experimental block, grouped by objective H, as indicated in the legend below panel A. Solid lines are across-block means, and dashed lines are sem.
Here we compare three GLMs in their efficiency for estimating average and individual Betas across trials as a function of trial variability, scan noise and Stimulus Onset Asynchrony (SOA): "Least Squares All" (LSA), "Least Squares Separate" (LSS) and "Least Squares Unitary" (LSU).
4 test trials) as a function of epoch, averaged across all networks.
Accuracy values were then averaged across all ten test groups to get an estimate of mean classification accuracy (based on 160 test trials) as a function of the number of features used.
We analysed subjective time estimates of actions (key presses) and outcomes (tones) on early and late test trials as a function of the surprisingness of that association during training.
Resting HR was similar prior to treatment (trial: p = 0.49, η p 2 = 0.08) but following treatment differed between trials as a function of time (trial × time: p = 0.03, η p 2 = 0.34; Table 1) such that the increase in HR was more pronounced during NIC-2 (6 ± 7 beats · min−1) and NIC-4 (7 ± 9 beats · min−1) compared to PLA.
Because we did not simulate the responses in each trial as a function of time, the outputs from the model are scalars on each trial.
This work demonstrates the development and use of a non-linear compartment model to quantitate the in vivo characteristics of an administered radiolabeled antibody in a pre-clinical murine cancer therapy trial as a function of the antibody dose.
Fig. 4A displays the raw average swimming speeds during the whole trial as a function of the genotype of animals under non-aversive circumstances (25°C).
